Trial Profile
A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CDX 301 (Primary) ; Glembatumumab vedotin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Varlilumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celldex Therapeutics Inc
- 28 Jan 2019 Results (n=62) assessing safety and efficacy of Glembatumumab Vedotin published in the Cancer.
- 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
- 07 Mar 2018 According to a Celldex Therapeutics media release, enrollment in the glembatumumab vedotin plus checkpoint inhibitor cohort has been completed.